Cargando…

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data

Detalles Bibliográficos
Autores principales:	Schalling, Martin, Gleiss, Andreas, Gisslinger, Bettina, Wölfler, Albert, Buxhofer-Ausch, Veronika, Jeryczynski, Georg, Krauth, Maria-Theresa, Simonitsch-Klupp, Ingrid, Beham-Schmid, Christine, Thiele, Jürgen, Gisslinger, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802530/ https://www.ncbi.nlm.nih.gov/pubmed/29233975 http://dx.doi.org/10.1038/s41408-017-0006-y

Ejemplares similares

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2016)

Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017)

Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia
por: Buxhofer‐Ausch, Veronika, et al.
Publicado: (2020)

Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'
por: Gisslinger, H, et al.
Publicado: (2017)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis
por: Geissler, Klaus, et al.
Publicado: (2020)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
por: Barbui, T, et al.
Publicado: (2015)

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
por: Them, Nicole CC, et al.
Publicado: (2015)

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
por: Hose, Dorothea, et al.
Publicado: (2020)

Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
por: Jeryczynski, G., et al.
Publicado: (2021)

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
por: Tefferi, A, et al.
Publicado: (2010)

Iron metabolism and iron supplementation in cancer patients
por: Ludwig, Heinz, et al.
Publicado: (2015)

Erratum to: Iron metabolism and iron supplementation in cancer patients
por: Ludwig, Heinz, et al.
Publicado: (2015)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2016)

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

Two common polymorphic variants of OATP4A1 as potential risk factors for colorectal cancer
por: Buxhofer-Ausch, Veronika, et al.
Publicado: (2020)

PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
por: Milosevic Feenstra, Jelena D., et al.
Publicado: (2022)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
por: McMullin, Mary Frances, et al.
Publicado: (2015)

Current and future treatment options for polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2015)

Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans
por: Kornienko, Aleksandra E., et al.
Publicado: (2016)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Duplex Reverse-Hybridization Assay for The Simultaneous Detection of KRAS/BRAF Mutations in FFPE-extracted Genomic DNA from Colorectal Cancer Specimens
por: Buxhofer-Ausch, Veronika, et al.
Publicado: (2013)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
por: Manshouri, Taghi, et al.
Publicado: (2022)

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
por: Vannucchi, Alessandro M., et al.
Publicado: (2019)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

Coexistence of Post-essential Thrombocythemia Myelofibrosis With Monoclonal Gammopathy of Undetermined Significance: A Case Report
por: Allam, Sarvani Reddy, et al.
Publicado: (2022)

Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia
por: Lekovic, Danijela, et al.
Publicado: (2023)

Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy: Breaking a dangerous bond
por: Jeryczynski, Georg, et al.
Publicado: (2022)

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
por: Haider, M, et al.
Publicado: (2016)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8oh65t7810g00u0o4q9r9o222p